Endoron Medical has secured $10m in Series A funding to advance its flagship product, the catheter-based EndoStapling solution Aortoseal, through clinical studies.
The round was led by Sofinnova Partners, with matching contributions from the European Innovation Council Fund (EIC Fund). This builds on a previously awarded €2.5m ($2.7m) grant by the European Commission under the EIC Accelerator programme, European Innovation Council and SMEs Executive Agency (EISMEA).
Related: Shifamed’s Adona Medical raises $33.5M
Endoron’s device is designed to help repair abdominal aortic aneurysms (AAA) using a minimally invasive stapling mechanism that seals endografts within the aorta, preventing movement and leaks. AAA is a dangerous swelling in the aorta that runs through the abdomen. Endografts are special tubes used to reinforce a weakened blood vessel from the inside.
The Israel-headquartered company was founded in 2019 and seed-financed in 2021 by Sofinnova Partners. The funding is set to advance Endoron’s technology through an Investigational device exemption (IDE) approved early feasibility study (EFS).
Endoron’s CEO Ronit Harpaz highlighted Sofinnova’s support: “With their continued support, I am confident we will reach key clinical and regulatory milestones as we advance our EndoStapling technology towards the clinic. The EIC’s participation further solidifies our commitment to bringing this innovative solution to the European market.”
